| Project/Area Number |
02670198
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Institute of Medical Science, University of Tokyo |
|---|
Principal Investigator |
TAKIGUCHI Masafumi Institute of Medical Science University of Tokyo, Dept. Tumor Biology Assistant Professor, 医科学研究所, 助手 (00183450)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KARIYONE Ai Institute of Medical Science, University of Tokyo Dept. Immunology Research Asso, 医科学研究所, 教務職員 (50114450)
|
|---|
| Project Period (FY) |
1990 – 1991
|
| Project Status |
Completed (Fiscal Year 1991)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1991: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1990: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | alloantigen / major histocomoptibility antigen / minor histocompatibility antigen / T cell clone / antigen recognition / HLA antigen / rejection |
|---|
| Research Abstract |
1)Recognition of HLA class I alloantigen by CTL clones.
We investigated the effects of single amino acid substitution of HLA-B35 antigen on recognition of HLA-B35 specific CTL clones. The results demonstrated that recognition of each CTL clones are affected by different amino acid substitutions, indicating that there is a large repertoire of alloreactive T cells for a given HLA class I antigen. Our studies support the concepts that multiple determinants are formed by the binding of various allopeptides to the HLA class I molecules.
2)Recognition of human minor histocompatibility(hmH)antigen by T cell clones.
We investigated the effects of single amino acid substitutions of HLA-B35 antigen on recognition of hmH antigen by hmH specific T cell clones. The substitutions at four residues which are peptide binding sites affects recognition of hmH specific T cell clones, indicating that hmH antigens are recognized as peptides. In fact, we succeeded in isolating the hmH peptide from donor derived B cell lines but not from patient's derived B cell lines.
|
